p16/pRb pathway alterations are required for bypassing senescence in human prostate epithelial cells

Cancer Research

Volumn 59, Issue 12, 1999, Pages 2957-2964

  Jarrard, David F ^a,c   Sarkar, Somdatta ^a   Shi, Yan ^a   Yeager, Thomas R ^a   Magrane, Gregg ^b   Kinoshita, Hidefumi ^a   Nassif, Nadine ^a   Meisner, Lorraine ^a   Newton, Michael A ^a   Waldman, Frederic M ^b   Reznikoff, Catherine A ^a  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CELL AGING; CELL CYCLE; CELL IMMORTALIZATION; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; REGULATOR GENE; SIGNAL TRANSDUCTION;

AGED; CELL AGING; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA METHYLATION; EPITHELIAL CELLS; GENE DELETION; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; ONCOGENE PROTEINS, VIRAL; PROSTATE; PROSTATIC NEOPLASMS; REPRESSOR PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0033564106     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Hayflick, L. The limited in vitro lifespan of human diploid cell strains. Exp. Cell Res., 25: 585-621, 1965.
2. Newbold, R. F., Overell, R. W., and Connell, J. R. Induction of immortality is an early event in malignant transformation of mammalian cells by carcinogens. Nature (Lond.), 299, 633-635, 1982.
3. Smith, J. R., and Pereira-Smith, O. M. Replicative senescence: implications for in vivo aging and tumor suppression. Science (Washington DC), 273: 63-67, 1996.
4. Dimri, G. P., and Campisi, J. Molecular and cell biology of replicative senescence. Cold Spring Harbor Symp. Quant. Biol., 59: 67-73, 1994.
5. Yeager, T. R., DeVries, S., Jarrard, D. F., Kao, C., Nakada, S. Y., Moon, T. D., Bruskewitz, R., Stadler, W. M., Meisner, L. F., Gilchrist, K. W., Newton, M. A., Waldman, F. M., and Reznikoff, C. A. Overcoming cellular senescence in human cancer pathogenesis. Genes Dev., 12: 163-174, 1998.
6. Reznikoff, C. A., Belair, C. D., Yeager, T. R., Savelieva, E., Blelloch, R. H., Puthenveettil, J. A., and Cuthill, S. A Molecular genetic model of human bladder cancer pathogenesis. Semin. Oncol., 23: 571-584, 1996.
7. Shay, J. W., Pereira-Smith, O. M., and Wright, W. E. A role for both RB and p53 in the regulation of human cellular senescence. Exp. Cell Res., 196: 33-39, 1991.
8. Kao, C., Huang, J., Wu, S. Q., Hauser, P., and Reznikoff, C. A. Role of SV40 T antigen binding to pRB and p53 in multistep transformation in vitro of human uroepithelial cells. Carcinogenesis (Lond.), 14: 2297-2302, 1993.
9. Reznikoff, C. A., Belair, C., Savelieva, E., Zhai, Y., Pfeifer, K., Yeager, T., Thompson, K. J., DeVries, S., Bindley, C., and Newton, M. A. Long-term genome stability and minimal genotypic and phenotypic alterations in HPV16 E7-, but not E6-, immortalized human uroepithelial cells. Genes Dev., 8: 2227-2240, 1994.
10. INK4A inactivation and telomerase activity are required to immortalize human epithelial cells. Nature (Lond.), 396: 84-88, 1998.
11. Alcorta, D. A., Xiong, Y., Phelps, D., Hannon, G., Beach, D., and Barrett, J. C. Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. Proc. Natl. Acad. Sci. USA, 93: 13742-13747, 1996.
12. Reznikoff, C. A., Yeager, T. R., Belair, C. D., Savelieva, E., Puthenveettil, J. A., and Stadler, W. M. Elevated p16 at senescence and loss of p16 at immortalization in human papillomavirus 16 E6, but not E7, transformed human uroepithelial cells. Cancer Res., 56: 2886-2890, 1996.
13. Tahara, H., Sato, E., Noda, A., and Ide, T. Increase in expression level of p21/cip1/waf1 with increasing division age in both normal and SV40-transformed human fibroblasts. Oncogene, 10: 835-840, 1995.
14. Brooks, J. D., Bova, G. S., Ewing, C. M., Piantadosi, S., Carter, B. S., Robinson, J. C., Epstein, J. I., and Isaacs, W. B. An uncertain role for p53 gene alterations in human prostate cancers. Cancer Res., 56: 3814-3822, 1996.
15. Cher, M. L., Bova, G. S., Moore, D. H., Small, E. J., Carroll, P. R., Pin, S. S., Epstein, J. I., Isaacs, W. B., and Jensen, R. H. Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res., 56: 3091-3102, 1996.
16. Brooks, J. D., Bova, G. S., and Isaacs, W. B. Allelic loss of the retinoblastoma gene in primary human prostatic adenocarcinomas. Prostate, 26: 35-39, 1995.
17. Cunningham, J. M., Shan, A. L., Wick, M. J., McDonnell, S. K., Schaid, D. J., Tester, D. J., Qian, J. Q., Takahashi, S., Jenkins, R. B., Bostwick, D. G., and Thibodeau, S. N. Allelic imbalance and microsatellite instability in prostatic adenocarcinoma. Cancer Res., 56: 4475-4482, 1996.
18. Aprikian, A. G., Sarkis, A. S., Fair, W. R., Zhang, Z. F., Fuks, Z., and Cordon-Cardo, C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. J. Urol., 151: 1276-1280, 1994.
19. Jarrard, D. F., Bova, G. S., Ewing, C. M., Pin, S. S., Nguyen, S. H., Herman, J. G., Cairns, P., Sidransky, D., Baylin, S. B., and Isaacs, W. B. Deletional, mutational and methylation analyses of CDKN2 in primary and metastatic prostate cancer. Genes Chromosomes Cancer, 19: 90-96, 1997.
20. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell, 88: 323-331, 1997.
21. Atadja, P., Wong, H., Garkavtsev, I., Veillette, C., and Riabowol, K. Increased activity of p53 in senescing fibroblasts. Proc. Natl. Acad. Sci. USA, 92: 8348-8352, 1995.
22. Hara, E., Tsurui, H., Shinozaki, A., Nakada, S., and Oda, K. Cooperative effect of antisense-Rb and antisense-p53 oligomers on the extension of life span in human diploid fibroblasts, TIG-1. Biochem. Biophys. Res. Commun., 179: 528-534, 1991.
23. Bond, J. A., Blaydes, J. P., Rowson, J., Haughton, M. F., Smith, J. R., Wynford-Thomas, D., and Wyllie, F. S. Mutant p53 rescues human diploid cells from senescence without inhibiting the induction of SKI1/WAF1. Cancer Res., 55: 2404-2409, 1995.
24. Brugarolas, J., Chandrasekaran, C., Gordon, J. I., Beach, D., Jacks, T., and Hannon, G. J. Radiation-induced cell cycle arrest compromised by p21 deficiency. Nature (Lond.), 377: 552-557, 1995.
25. Cristofalo, V. J., Pignolo, R. J., Cianciarulo, F. L., DiPaolo, B. R., and Rotenberg, M. O. Changes in gene expression during senescence in culture. Exp. Gerontol., 27: 429-432, 1992.
26. Stein, G. H., Beeson, M., and Gordon, L. Failure to phosphorylate the retinoblastoma gene product in senescent human fibroblasts. Science (Washington DC), 249: 666-669, 1990.
27. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
28. Hara, E., Smith, R., Parry, D., Tahara, H., Stone, S., and Peters, G. Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol. Cell. Biol., 16: 859-867, 1996.
29. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
30. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
31. Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., and Barlek, J. Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (Lond.), 375: 503-506, 1995.
32. Ruas, M., and Peters, G. The p16/CDKN2 tumor suppressor gene and its relatives. Biochim. Biophys. Acta, 1378: F115-F117, 1998.
33. Theodorescu, D., Broder, S. R., Boyd, J. C., Mills, S. E., and Frierson, H. F., Jr. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. J. Urol., 158: 131-137, 1997.
34. Peehl, D. M., and Stamey, T. A. Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell. Dev. Biol., 22: 82-90, 1986.
35. Peehl, D. M., Wong, S. T., and Stamey, T. A. Clonal growth characteristics of adult human prostatic epithelial cells. In Vitro Cell. Dev. Biol., 24: 530-536, 1988.
36. Reznikoff, C. A., Johnson, M. D., Norback, D. H., and Bryan, G. T. Growth and characterization of normal human urothelium in vitro. In Vitro, 19: 326-343, 1983.
37. Umbas, R., Schalken, J. A., Aalders, T. W., Carter, B. S., Karthaus, H. F., Schaafsma, H. E., Debruyne, F. M., and Isaacs, W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104-5109, 1992.
38. Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., and Pereira-Smith, O. A biomarker that identifies senescent human cells in culture and in aging skin in vivo. Proc. Natl. Acad. Sci. USA, 92: 9363-9367, 1995.
39. Halbert, C. L., Demers, G. W., and Galloway, D. A. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J. Virol., 65: 473-478, 1991.
40. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
41. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockertn, E., Day, R. S., III, Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
42. Kallioniemi, A., Kallioniemi, O. P., Piper, J., Tanner, M., Stokke, T., Chen, L., Smith, H. S., Pinkel, D., Gray, J. W., and Waldman, F. M. Detection and mapping of amplified DNA sequences in breast cancer by comparative genomic hybridization. Proc. Natl. Acad. Sci. USA, 91: 2156-2160, 1994.
43. Hovey, R. M., Chu, L., Balazs, M., DeVries, S., Moore, D., Sauter, G., Carroll, P. R., and Waldman, F. M. Genetic alterations in primary bladder cancers and their metastases. Cancer Res., 58: 3555-3560, 1998.
44. Newton, M. A., Gould, M. N., Reznikoff, C. A., and Haag, J. D. On the statistical analysis of allelic-loss data. Stat. Med., 17: 1425-1445, 1998.
45. Bonkhoff, H., Stein, U., and Remberger, K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate: simultaneous demonstration of cell-specific epithelial markers. Hum. Pathol., 25: 42-46, 1994.
46. Verhagen, A. P., Ramaekers, F. C., Aalders, T. W., Schaafsma, H. E., Debruyne, F. M., and Schalken, J. A. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res., 52: 6182-6187, 1992.
47. Shay, J. W., Wright, W. E., Brasiskyte, D., and Van der Haegen, B. A. E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene, 8: 1407-1413, 1993.
48. Vousden, K. H. Regulation of the cell cycle by viral oncoproteins. Semin. Cancer Biol., 6: 109-116, 1995.
49. Bookstein, R., Rio, P., Madreperla, S. A., Hong, F., Allred, C., Grizzle, W. E., and Lee, W. H. Promoter deletion and loss of retinoblastoma gene expression in human prostate carcinoma. Proc. Natl. Acad. Sci. USA, 87: 7762-7766, 1990.
50. Isaacs, W. B., Carter, B. S., and Ewing, C. M. Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res., 51: 4716-4720, 1991.
51. Cairns, P., Mao, L., Merlo, A., Lee, D. J., Schwab, D., Eby, Y., Tokino, K., van der Riet, P., Blaugrund, J. E., and Sidransky, D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss. Science (Washington DC), 265: 415-417, 1994.
52. Vocke, C. D., Pozzatti, R. O., Bostwick, D. G., Florence, C. D., Jennings, S. B., Strup, S. E., Duray, P. H., Liotta, L. A., Emmert-Buck, M. R., and Linehan, W. M. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res., 56: 2411-2416, 1996.
53. Boring, C. C., Squires, T. S., Tong, T., and Montgomery, S. Cancer statistics, 1994. CA Cancer J. Clin., 44: 7-26, 1994.
54. Okamoto, A., Demetrick, D. J., Spillare, E. A., Hagiwara, K., Hussain, S. P., Bennett, W. P., Forrester, K., Gerwin, B., Serrano, M., and Beach, D. H. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA, 91: 11045-11049, 1994.
55. Medcalf, A. S., Klein-Szanto, A. J., and Cristofalo, V. J. Expression of p21 is not required for senescence of human fibroblasts. Cancer Res., 56: 4582-4585, 1996.
56. Gonzalgo, M. L., Hayashida, T., Bender, C. M., Pao, M. M., Tsai, Y. C., Gonzales, F. A., Nguyen, H. D., Nguyen, T. T., and Jones, P. A. The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Res., 58: 1245-1252, 1998.
57. Caldas, C., Hahn, S. A., da Costa, L. T., Redston, M. S., Schutte, M., Seymour, A. B., Weinstein, C. L., Hruban, R. H., Yeo, C. J., and Kern, S. E. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat. Genet., 8: 27-32, 1994.
58. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H., Jr., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
59. Liu, Q., Neuhausen, S., McClure, M., Frye, C., Weaver-Feldhaus, J., Gruis, N. A., Eddington, K., Allalunis-Turner, M. J., Skolnick, M. H., Fujimura, F. K., and Kamb, A. CDKN2 (MTS1) tumor suppressor gene mutations in human tumor cell lines. Oncogene, 11: 2455-2461, 1995.
60. Nishizaki, T., DeVries, S., Chew, K., Goodson, W. H., III, Ljung, B. M., Thor, A., and Waldman, F. M. Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer, 19: 267-272, 1997.
61. Collins, C., Rommens, J. M., Kowbel, D., Godfrey, T., Tanner, M., Hwang, S. I., Polikoff, D., Nonet, G., Cochran, J., Myambo, K., Jay, K. E., Froula, J., Cloutier, T., Kuo, W. L., Yaswen, P., Dairkee, S., Giovanola, J., Hutchinson, G. B., Isola, J., Kallioniemi, O. P., Palazzolo, M., Martin, C., Ericsson, C., Pinkel, D., and Gray J. W. Positional cloning of ZNF217 and NABC1: genes amplified at 20q13.2 and overexpressed in breast carcinoma. Proc. Natl. Acad. Sci. USA, 95: 8703-8708, 1998.
62. Belair, C. D., Yeager, T. R., Lopez, P. M., and Reznikoff, C. A. Telomerase activity: a biomarker of cell proliferation, not malignant transformation. Proc. Natl. Acad. Sci. USA, 94: 13677-13682, 1997.
63. Wang, J., Xie, L. Y., Allan, S., Beach, D., and Hannon, G. J. Myc activates telomerase. Genes Dev., 12: 1769-1774, 1998.
64. Ittmann, M. M., and Wieczorek, R. Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum. Pathol., 27, 28-34, 1996.
65. Parry, D., Bates, S., Mann, D. J., and Peters, G. Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. EMBO J., 14: 503-511, 1995.